Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143255 | 0.92 | KDM4E (0.45) | KDM4EALDH1A1HPGDCRHBPCRHR2 | |
| SCHEMBL31156243 | 0.82 | EGLN1 (0.39) | MAPK8MAPK9MAPK10FGFR4KDM4E | |
| SCHEMBL1143262 | 0.82 | XDH (0.46) | KDM4EALDH1A1HPGDTDP1LMNA | |
| SCHEMBL1142962 | 0.81 | ALDH1A1 (0.44) | MAPK8MAPK9MAPK10KDM4EALDH1A1 | |
| SCHEMBL15662848 | 0.79 | CSNK2A2 (0.52) | MAPK8MAPK9MAPK10KDM4EALDH1A1 | |
| SCHEMBL1143106 | 0.78 | XDH (0.44) | HCAR3KDM4EALDH1A1HPGDCRHBP | |
| SCHEMBL2528389 | 0.78 | SMN1; SMN2 (0.46) | KDM4EALDH1A1HPGDLMNAL3MBTL1 | |
| SCHEMBL12869979 | 0.76 | XDH (0.45) | KDM4ELMNAXDH | |
| SCHEMBL13568491 | 0.76 | HTT (0.58) | MAPK8MAPK9KDM4EALDH1A1HPGD | |
| SCHEMBL1143188 | 0.73 | ALDH1A1 (0.43) | MAPK8MAPK9MAPK10HCAR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340505-B2 | Type III secretion inhibitors, analogs and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340505-B2 | Type III secretion inhibitors, analogs and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140323483-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323483-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2014-10-30 | — | — | US | disclosed |
| US-8716283-B2 | Type III secretion inhibitors, analogs and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2009145829-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | MAPK8 1967/4885MAPK9 1583/4885MAPK10 2145/4885 |
| US-20140323483-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | MAPK8 1967/4885MAPK9 1583/4885MAPK10 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.